Duodenum-preserving pancreatic head resection and resection of the head of the pancreas combined with segmental duodenectomy

Kozlov, I. A.; Шевченко, Т. В.; Baydarova, M.; Vishnevsky, V.; Zhao, Alexey V

doi:10.1016/j.hpb.2019.10.811

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… ND no data **Partial head resection processus uncinatus † Laparoscopic DPPHR †† Control group: [ 36 ], 12 pats. enucleation; [ 37 ], 15 pats. DPPHRt+SD; [ 43 ], 13 pats.…”

Section: Methodsmentioning

confidence: 99%

Long-Term Oncologic Outcome following Duodenum-Preserving Pancreatic Head Resection for Benign Tumors, Cystic Neoplasms, and Neuroendocrine Tumors: Systematic Review and Meta-analysis

Beger,

Mayer,

Poch

2024

Ann Surg Oncol

View full text Add to dashboard Cite

Background Pancreatoduodenectomy (PD) has a considerable surgical risk for complications and late metabolic morbidity. Parenchyma-sparing resection of benign tumors has the potential to cure patients associated with reduced procedure-related short- and long-term complications. Materials and Methods Pubmed, Embase, and Cochrane libraries were searched for studies reporting surgery-related complications following PD and duodenum-preserving total (DPPHRt) or partial (DPPHRp) pancreatic head resection for benign tumors. A total of 38 cohort studies that included data from 1262 patients were analyzed. In total, 729 patients underwent DPPHR and 533 PD. Results Concordance between preoperative diagnosis of benign tumors and final histopathology was 90.57% for DPPHR. Cystic and neuroendocrine neoplasms (PNETs) and periampullary tumors (PATs) were observed in 497, 89, and 31 patients, respectively. In total, 34 of 161 (21.1%) patients with intraepithelial papillar mucinous neoplasm exhibited severe dysplasia in the final histopathology. The meta-analysis, when comparing DPPHRt and PD, revealed in-hospital mortality of 1/362 (0.26%) and 8/547 (1.46%) patients, respectively [OR 0.48 (95% CI 0.15–1.58); p = 0.21], and frequency of reoperation of 3.26 % and 6.75%, respectively [OR 0.52 (95% CI 0.28–0.96); p = 0.04]. After a follow-up of 45.8 ± 26.6 months, 14/340 patients with intraductal papillary mucinous neoplasms/mucinous cystic neoplasms (IPMN/MCN, 4.11%) and 2/89 patients with PNET (2.24%) exhibited tumor recurrence. Local recurrence at the resection margin and reoccurrence of tumor growth in the remnant pancreas was comparable after DPPHR or PD [OR 0.94 (95% CI 0.178–5.34); p = 0.96]. Conclusions DPPHR for benign, premalignant neoplasms provides a cure for patients with low risk of tumor recurrence and significantly fewer early surgery-related complications compared with PD. DPPHR has the potential to replace PD for benign, premalignant cystic and neuroendocrine neoplasms.

show abstract

“… ND no data **Partial head resection processus uncinatus † Laparoscopic DPPHR †† Control group: [ 36 ], 12 pats. enucleation; [ 37 ], 15 pats. DPPHRt+SD; [ 43 ], 13 pats.…”

Section: Methodsmentioning

confidence: 99%